Adenovirus News and Research

RSS

Adenoviruses most commonly cause respiratory illness; however, depending on the infecting serotype, they may also cause various other illnesses, such as gastroenteritis, conjunctivitis, cystitis, and rash illness. Symptoms of respiratory illness caused by adenovirus infection range from the common cold syndrome to pneumonia, croup, and bronchitis. Patients with compromised immune systems are especially susceptible to severe complications of adenovirus infection. Acute respiratory disease (ARD), first recognized among military recruits during World War II, can be caused by adenovirus infections during conditions of crowding and stress.

Will mRNA vaccine boosters be required for SARS-CoV-2 variants?

A new study shows that the highly effective mRNA Moderna vaccine designed against the original SARS-CoV-2 strain may lose some efficacy as new variants arise.

30 Aug 2021

Sustained and effective response to Janssen COVID-19 vaccine Is enhanced by delayed booster

A new study adds to the data on the optimum interval between the first and second doses of the adenovirus vectored COVID-19 vaccine.

30 Aug 2021

Nanotechnology provides novel solutions against zoonotic viruses

Therefore, scientists functionalize nanoparticles to act against these pathogenic viruses in a clinical strategy. In a recent review published in the journal Microbial Pathogenesis, researchers look at the novel solutions against zoonotic viruses provided by nanotechnology.

23 Aug 2021

SARS-CoV-2 antibodies found to neutralize bat coronavirus (RaTG13) in new study

A striking new study examines how far antibodies elicited by vaccines against the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), or by natural infection, can neutralize the closely related bat coronavirus (CoV) RaTG13.

19 Aug 2021

Early clinical trial data in for whole virus COVID-19 vaccine candidate

In a study uploaded to the preprint server medRxiv*, the efficacy of a whole virion Coronavirus vaccine was determined by giving the vaccine to healthy adult volunteers, which generated a robust immune response with evidence of T-cell activation.

19 Aug 2021

The White House says boosters for all. Here’s what you need to know.

The Biden administration announced plans Wednesday to offer boosters to all U.S. adults as soon as next month, saying that recent data, including some made available only in the past few days, played a role in that decision.

18 Aug 2021

Rush to boosters sparks confusion, differing recommendations

When the Food and Drug Administration announced last week that a third dose of Moderna or Pfizer-BioNTech covid-19 vaccine may boost the immunity of some people who are immunocompromised, officials repeated their stance that fully vaccinated, healthy people do not need another dose.

18 Aug 2021

Obtained SARS-CoV-2 immunity, naturally or via vaccination persists 12 months

In a research paper recently uploaded to the preprint server medRxiv* by Havervall et al. (August 12th, 2021), neutralizing antibody titers towards wild-type SARS-CoV-2 and several variants of concern in individuals having either been vaccinated or infected with mild COVID-19 one year earlier are assessed, finding a reduced neutralization capacity against some strains.

16 Aug 2021

Response to a third SARS-CoV-2 vaccine dose amongst immunocompromised

In a research paper recently uploaded to the preprint server medRxiv* by Schrezenmeier et al. (August 12th, 2021) the potential benefit of three vaccine doses in either a homogenous or heterogeneous dosing regimen amongst kidney transplant patients is assessed, finding that the search for viable vaccination approaches amongst these patients remains an urgent medical need.

16 Aug 2021

VPS29 gene facilitates coronavirus cell entry

In a research paper recently uploaded to the bioRxiv* preprint server by Poston et al. (August 8th, 2021), common host factors amongst several zoonotic pathogens are explored by CRISPR-Cas9 screening in human lung cells, focusing in particular on the betacoronavirus genus.

11 Aug 2021

Natural vs. vaccine-induced COVID-19 immunity

A new paper discusses the protection offered by immunity against COVID-19 following vaccination as compared to natural infection.

10 Aug 2021

SARS-CoV-2 variants and their ability to infect mice

A new study published on the bioRxiv* preprint server has conducted in silico studies along with in vitro, in vivo, and in situ observations and indicated the mouse adaptation of SARS-CoV-2.

10 Aug 2021

Dialysis patients' response to COVID19 vaccine type

The researchers at Standford University evaluated the humoral vaccination response of 2,099 fully vaccinated patients undergoing dialysis.

5 Aug 2021

Vaccinia-based COVID-19 vaccines confer immunity in hamster model

In a paper recently uploaded to the preprint server bioRxiv* by Kulkarni et al. (August 3, 2021), the potential of vaccinia virus-based vaccines expressing the full-length SARS-CoV-2 spike protein is examined in mice and Syrian hamsters. The findings report that the vaccine generates high titers of neutralizing antibodies with good activity towards SARS-CoV-2 variants of concern.

5 Aug 2021

Heterologous prime-boost vaccination induces robust mucosal and systemic immunity against SARS-CoV-2

Scientists from Germany and Italy recently demonstrated the benefits of intramuscular/intranasal heterologous prime-boost vaccination regimen against coronavirus disease 2019 (COVID-19).

4 Aug 2021

One billion doses of Oxford-AstraZeneca COVID-19 vaccine released

The University of Oxford's and our partners AstraZeneca have today announced that one billion doses of the ChAdOx1 nCov-19 coronavirus vaccine have been released, to more than 170 countries, marking a key milestone as part of the University and AstraZeneca's joint vision to make the available to the world, on a not-for-profit basis for the world during the pandemic, and in perpetuity for low- and middle-income countries.

4 Aug 2021